Samso News: Proteomics International — Canadian Patent Granted for PromarkerEso - A Precision Diagnostics Business - Market Penetration
- Noel Ong
- 3 days ago
- 5 min read
Announcement
Canadian patent secured for PromarkerEso test for EAC – 16 January 2026 (view the announcement)
Samso News continues to follow Proteomics International with the latest ASX update on the expansion of PromarkerEso’s patent coverage into Canada, strengthening the Company’s North American positioning and supporting its broader multi-test commercial rollout strategy.
Proteomics International and the Precision Diagnostics storyhave featured heavily on the Samso platform over time, and it is good to see that the stock has been appreciating in value since late November. For those in the Samso community who did take a position, it is looking good with this latest ASX update.
The Business of Proteomics International: Precision Diagnostics Commercialisation
Proteomics International (ASX: PIQ) is a precision diagnostics company focused on the development and commercial launch of first-in-class blood-based diagnostic tests targeting diseases that are often detected late and are costly to manage (Figure 1).
The Company operates a platform-based model, combining proprietary biomarkers, validated clinical data, accredited laboratories, and a digital sales pathway to support direct sales and future licensing across multiple tests and jurisdictions.
Figure 1: Proteomics International’s business model, where several first-in-class diagnostic tests are supported by shared clinical validation, intellectual property, and commercial systems. (source: PIQ)
Highlights – Canadian Patent Secures IP for PromarkerEso in a High-Need Market
Canadian patent granted for PromarkerEso, protecting intellectual property until November 2035.
PromarkerEso is a first-in-class blood test designed to detect esophageal adenocarcinoma, including early-stage disease.
Figure 2: PromarkerEso (source: PIQ)
Patent coverage now spans Australia, Canada, China, Hong Kong, Europe, and the United States, supporting global commercialisation.
Esophageal adenocarcinoma has a five-year survival rate of less than 20%, with up to 90% of cases undetected until late stage, using current screening approaches.
The patent underpins PIQ’s North American strategy, enabling direct sales, partnerships, and future licensing opportunities.
Near-term Milestones to Watch
(Figure 3)
Continued commercial ramp-up of PromarkerEso following launches in Australia and planned expansion in North America.
Progress toward US regulatory and reimbursement pathways, including PLA code applications.
Growth in direct sales and strategic partnering discussions for Promarker diagnostic tests.
Advancement of licensing opportunities as tests gain market traction
Figure 3: Milestones – Multiple Value Drivers Achieved & Ahead (source: PIQ)
Samso Concluding Comments
This ASX update is all about the Canadian patent strengthening the protection around PromarkerEso in a key healthcare market. It would be logical that PIQ will want to extend the geographic reach of the Company’s intellectual property portfolio. The future of the business is all about having the upper hand against any competition. With the rising market interest recently, this should add more to the value creation journey.
Esophageal adenocarcinoma remains difficult to detect early using current methods, and PromarkerEso is designed to address this gap with a blood-based approach. I am now a big proponent to whole ASX medical sector as this is starting to make a lot more sense than the hit and miss world of small-cap mineral explorers.
Market Implication - The Investor Lens
The increased market attention that has moved the share price of PIQ in late November is hopefully something that is simply setting the stage for bigger and better things for shareholders.
Figure 4: PIQ share price chart as of 23rd January 2026. (source: CommSec)
With a current market capitalisation of AUD $119.5M, I think there is still a way to go in terms of a sustained market valuation. The global precision diagnostics and medicine market was valued at ~USD 122.6 billion in 2024. According to Global Market Insights, it is expected to expand significantly toward ~USD 448 billion by 2034 at a ~13.5% CAGR. Precision diagnostics (which includes blood-based diagnostics) is a multi-hundred-billion-dollar market with strong growth prospects, driven by oncology testing, personalized medicine, and molecular assays.
The Samso Way – Seek the Research
Here at Samso, we pride ourselves on delivering content for investors that is independent and informed by over three decades of experience in the industry. Our content is well-researched and is only created if I see merit in discussing the company's story.
Our mission is simple: cut through the noise and spotlight what matters—genuine stories, grounded insights, and real opportunity.
Our content is well-researched and is only created if the team sees merit in discussing the company or concept. Investors can explore our three core platforms:
There may be numerous paths to success in investing, but the common thread among successful individuals is that they remain committed to making informed decisions. Equip yourself with the right knowledge and tools, and you will be well on your way to achieving your financial goals.
Most importantly, investors need to be absolutely diligent in understanding their own risk-reward tolerance and capabilities. Never bite off more than you can chew. As they say, Rome wasn’t built in a day, and the Great Wall stood because it took centuries to complete.
The Samso Philosophy:
Stay curious. Stay sharp. And remember—digging deeper always uncovers the real value.
In Life, there is no such thing as a Free Lunch.
Never bite off more than you can chew is my parting comment.
Happy Investing, and the only four-letter word you need to know is DYOR.
To support our independent nature of our work, please head over to our Support Page and give us a helping hand in any of the ways listed. This is a new initiate for the Samso Platform, and it was always the concept of Samso when we started this journey in 2018.
Disclaimer
The information or opinions provided herein do not constitute investment advice, an offer, or solicitation to subscribe for, purchase, or sell the investment product(s) mentioned herein. It does not take into consideration, nor have any regard to your specific investment objectives, financial situation, risk profile, tax position and particular, or unique needs and constraints.
Share to Grow: Your Bonus
Samso has just released an eBook: How to Add Value to your Share Portfolio
A lesson on geological models sought by mining companies that gives insight and an understanding of which portfolios are better - and potentially more lucrative – investments. Click here to download this eBook.
If you find this article informative and useful, please help me share the information. I try to write about topics that are interesting and have the potential to be of investment value. It is not easy to find stories that fit those parameters. If you or your organisation sees the benefit of what Samso is trying to achieve and has a need to share your journey, please contact me at noel.ong@samso.com.au.
Samso is a trusted platform that equips dedicated investors with up-to-date industry knowledge and insights from top CEOs and thought leaders. By staying informed on business advancements and market trends, investors can enhance their financial decisions through a combination of expert guidance and their own research.
Comments